Alanine and glutamine synthesis and release from skeletal muscle. IV. beta-Adrenergic inhibition of amino acid release.
Alanine and glutamine formation and release were studied using the intact epitrochlaris preparation of rat skeletal muscle. Epinephrine reduced the release of alanine and glutamine in a concentration-dependent manner. Measurable inhibition was observed at 10(-9) M epinephrine, and maximal inhibition was obtained at 10(-5) M. Norepinephrine also reduced alanine and glutamine formation and release but the concentration required for maximal inhibition was approximately 100-fold greater than for epinephrine. Isoproterenol (beta agonist), but not phenylephrine (alpha agonist), reproduced the effects of epinephrine, and propranolol (beta antagonist), but not phentolamine (alpha antagonist), blocked the effect of the catecholamine. N6,O2'-Dibutyryl adenosine 3':5'-monophosphate reproduced the effects of epinephrine and theophylline potentiated the effect of submaximal concentrations of the hormone. Glucagon and prostaglandin E2 had no observable effect on amino acid release. Insulin did not modify the inhibition of alanine and glutamine release produced by epinephrine. Alanine and glutamine formation from added precursor amino acids was unaffected by epinephrine or cyclic adenosine 3':5'-monophosphate. Epinephrine reduced alanine formation in muscles obtained from diabetic rats or animals treated with thyroxine or cortisone. These findings indicate that physiological levels of catecholamines reduce alanine and glutamine formation and release from skeletal muscle. This effect is mediated by a beta-adrenergic receptor and the adenylate cyclase system and can be accounted for by an inhibition of muscle protein degradation.
D000409:Alanine / Q000378:metabolism*; D000818:Animals; D003994:Bucladesine / Q000494:pharmacology; D003348:Cortisone / Q000494:pharmacology; D003920:Diabetes Mellitus / Q000378:metabolism; D004837:Epinephrine / Q000494:pharmacology*; D005934:Glucagon / Q000494:pharmacology; D005973:Glutamine / Q000378:metabolism*; D066298:In Vitro Techniques; D007545:Isoproterenol / Q000494:pharmacology; D007773:Lactates / Q000378:metabolism; D008297:Male; D009132:Muscles / Q000187:drug effects / Q000378:metabolism*; D009638:Norepinephrine / Q000494:pharmacology; D010646:Phentolamine / Q000494:pharmacology; D010656:Phenylephrine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011458:Prostaglandins E / Q000494:pharmacology; D011773:Pyruvates / Q000378:metabolism; D051381:Rats; D013806:Theophylline / Q000494:pharmacology; D013974:Thyroxine / Q000494:pharmacology
D007773:Lactates; D011458:Prostaglandins E; D011773:Pyruvates; D005973:Glutamine; D010656:Phenylephrine; D003994:Bucladesine; D005934:Glucagon; D011433:Propranolol; D013806:Theophylline; D007545:Isoproterenol; D000409:Alanine; D013974:Thyroxine; D003348:Cortisone; D009638:Norepinephrine; D004837:Epinephrine; D010646:Phentolamine